Business Context and Reporting Period
TransCode Therapeutics, Inc. filed a Form 8-K dated October 27, 2023, reporting an October 26, 2023 notification from The Nasdaq Stock Market’s Hearings Panel. The company’s common stock trades under the symbol RNAZ on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, cash, liquidity, or other operating financial metrics. It addresses the company’s compliance with Nasdaq’s stockholders’ equity requirement.
- Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million of stockholders’ equity for continued listing on the Nasdaq Capital Market.
- The filing does not state the company’s current stockholders’ equity or quantify any financing, restructuring, or other actions intended to restore compliance.
Material Changes and Nasdaq Status
- On May 16, 2023, Nasdaq notified the company that it was not in compliance with the $2.5 million stockholders’ equity requirement.
- The company submitted a compliance plan on June 30, 2023, supplemented on July 24, 2023. Nasdaq rejected the plan and denied an extension on July 26, 2023, subjecting the shares to potential delisting.
- After a Nasdaq hearing held on October 5, 2023, the Hearings Panel granted an exception and extended continued listing through January 22, 2024, subject to specified reporting conditions.
Guidance, Outlook, Risks, and Unusual Items
- The company must provide Nasdaq a detailed update by November 14, 2023, regarding its efforts to meet the stockholders’ equity requirement.
- By January 22, 2024, the company must provide an update demonstrating long-term compliance.
- The Panel stated it cannot grant continued listing beyond January 22, 2024 if the company has not regained compliance. It also reserved the right to reconsider the exception if circumstances make continued listing inadvisable or unwarranted.
- The company must promptly notify Nasdaq of significant events that could affect compliance or its ability to satisfy the exception’s terms.
- Management cautioned that there can be no assurance the company will regain compliance or that its plan for long-term compliance will be accepted. Failure to comply could result in delisting from Nasdaq.
- The filing contains forward-looking statements concerning the company’s plans and ability to regain compliance and incorporates risk disclosures from its Form 10-K for the year ended December 31, 2022 and subsequent SEC filings.
Investor Verification Items
- Verify the company’s actual stockholders’ equity and the actions taken to increase it to at least $2.5 million.
- Verify whether the November 14, 2023 update and January 22, 2024 long-term compliance update were submitted and accepted by Nasdaq.
- Monitor Nasdaq’s final determination and any subsequent delisting, appeal, trading-status, or financing disclosures.
- Review subsequent SEC filings for liquidity, capital-raising activity, dilution, going-concern risks, and other events affecting Nasdaq compliance.